Oman is regulated by the Ministry of Health’s Directorate General of Pharmaceutical Affairs and Drug Control, working through its Drug Safety Center. Of the Gulf states, Oman publishes the clearest and most complete regulatory guidance — which makes it a comparatively predictable market to plan for, provided you meet its technical requirements.
Raised Pharma supports manufacturers and brand owners preparing for Oman: classification, eCTD dossier preparation, Zone IV stability testing, GMP evidence and Arabic labelling.
Oman’s regulatory framework names Health Canada among its recognised Reference Health Authorities, alongside the US FDA, EMA, TGA, MHRA, Japan’s PMDA, Saudi SFDA and Swissmedic.
The practical benefit is concrete: Oman’s default position is to inspect your manufacturing site, but a GMP inspection waiver is available where the company holds a valid approval or inspection outcome issued within the last two years by one of those reference authorities, with no outstanding quality complaints or adverse drug reactions.
One honest caveat we will not gloss over. Health Canada’s status as a Reference Health Authority applies to the GMP inspection waiver. Oman’s faster verification and abridged product registration pathways are written specifically around FDA and EMA approval — not Health Canada. We would need to confirm with the Drug Safety Center whether a Health Canada authorisation alone opens those routes for your product. Anyone telling you that a Canadian licence automatically fast-tracks an Omani filing is over-promising.
Oman’s classification guideline creates “health products” as a separate class from pharmaceutical medicines, herbal medicines and medical devices — all under the same regulator.
Dietary supplements qualify as health products when presented in defined dosage forms (capsules, tablets, powders, liquids) and within specified vitamin and mineral dose ranges by life stage. Products exceeding the maximum dosages, or making high-level medical claims, are reclassified as pharmaceutical medicines — a substantially heavier pathway.
Classification turns on five stated principles: therapeutic claims, composition, level of action, how other authorities have classified it, and precedent from similar registered products. That fourth principle is worth noting — how your product is classified in Canada or the EU is a factor Oman will actually consider.
Oman requires submission in eCTD format, structured as ICH Modules 2 to 5 plus the GCC Module 1 regional specification. Once an eCTD submission has been received for a product, reverting to a non-eCTD format is not accepted for subsequent submissions on that product.
For a company filing its first Gulf dossier, this is the single biggest technical hurdle. eCTD is not simply a folder of PDFs — it is a validated electronic structure with its own lifecycle rules.
Stability data must follow the GCC Guidelines for Stability Testing, Zone IV (hot and humid).
This catches out companies whose existing data was generated for temperate markets. A stability package built for Canada or Northern Europe will not automatically satisfy Zone IV, and stability studies cannot be compressed — they take the time they take. If Oman or the wider Gulf is in your plan, Zone IV conditions should be built into your stability protocol from the start, not retrofitted after a deficiency letter.
Oman operates a strict two-stage sequence. The manufacturer must be registered with the Ministry of Health before any product application can proceed: application, business validation, assessment, Technical Committee decision, then GMP inspection unless waived. Product registration follows: technical and business validation, departmental assessment, committee review, price determination, certificate.
A local authorised agent is required — Oman’s government portal states the service is for authorised local agents of pharmaceutical companies and local pharmaceutical factories. The agent’s name must also appear on the Arabic outer packaging.
An Arabic translation of the outer packaging information is required for all medicines except those intended solely for hospital use. Arabic is required on the outer pack (product name, strength, form, pack size, storage, price, agent and marketing authorisation holder name, registration number), on blister strips (name and strength), and on small containers under 10 ml. The Ministry publishes an Arabic patient information leaflet template.
Unusually, Oman states its rejection triggers explicitly:
Add to that stability data not meeting Zone IV, and incomplete Arabic labelling or PIL.
This is a useful illustration of why we do not publish Gulf timelines. Three different official Omani government sources currently give three different figures for the same registration process. They are all official, and they are all of differing vintage. Quoting any one of them to you would be misleading.
What we can tell you honestly is what actually drives the schedule: dossier completeness, whether your GMP evidence qualifies for a waiver, whether your stability data meets Zone IV, and how quickly you answer deficiency questions. Current timelines and fees must be confirmed with the Drug Safety Center.
Email: info@raisedpharma.com Phone: +1 (716)-777-4800
Request a consultation See all GCC markets
Important: General information about the Omani regulatory environment, not regulatory or legal advice. Requirements change. Classification, dossier content, GMP waiver eligibility, stability design, labelling and claims must be reviewed by a qualified regulatory professional and confirmed with the Ministry of Health Drug Safety Center before filing. Whether Health Canada authorisation qualifies for the verification or abridged pathways requires specific confirmation. Last reviewed August 2026.